Ainos, INC 8-K filings

Ainos, Inc. announced its second quarter 2026 financial results, revealing a substantial decrease in revenue and an increased net loss, while highlighting continued progress in its AI Nose technology deployments.

Ainos, Inc. announced the dismissal of YCM CPA INC. as its independent registered public accounting firm and the engagement of DLEE Accountancy, Inc. on July 9, 2026.

Ainos, Inc. has entered into a short-term unsecured credit facility agreement with CTBC Bank for NT$62,000,000, approximately US$1.94 million, to bolster its financial flexibility.

Ainos, Inc. announced its first quarter 2026 financial results, highlighting progress in AI Nose deployments across semiconductor and healthcare infrastructure markets, alongside a strategic financing arrangement.

Ainos, Inc. has entered into a three-year distribution agreement with Trusval Technology Co. Ltd. for its AINOS AI Nose and related products and services, including one-year exclusive rights for certain clients.

Ainos, Inc. announced its long-term platform strategy to digitize smell and establish scent as a native data language for artificial intelligence.

Ainos, Inc. announced the issuance of 1.16 million common shares to its wholly-owned subsidiary, ScentAI Inc., in an unregistered transaction.

Ainos, Inc. reported its third quarter 2025 financial results, highlighting accelerated commercialization of its AI Nose technology and strategic partnerships.

Ainos, Inc. and Taiwan Carbon Nano Technology Corporation (TCNT) amended their product development agreement, setting a new patent licensing fee of $50,000 per month for two years.

Ainos, Inc. has increased its At-The-Market offering capacity by an additional $874,496, bringing the total potential capital raise to over $2.7 million.

Ainos, Inc. announced its second quarter 2025 financial results, highlighting the commercialization of its AI Nose platform with new revenue streams and strategic partnerships.

Ainos, Inc. announced a three-year, $2.1 million subscription-based order with ASE Technology Holding Co., Ltd. for the deployment of its AI Nose platform in semiconductor manufacturing.

Ainos, Inc. has engaged YCM CPA Inc. as its new independent registered public accounting firm, effective July 31, 2025, following the resignation of KCCW Accountancy Corp. due to its exit from public company audit practice.

Ainos, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement and detailed a 90-day roadmap to scale its AI Nose platform for 2026 commercialization, driven by new strategic partnerships and significant revenue growth.

Ainos, Inc. has enacted a 1-for-5 reverse stock split of its common stock, effective June 30, 2025, to consolidate outstanding shares and adjust its capital structure.

Ainos, Inc. has announced a legally binding strategic partnership with Kenmec Mechanical Engineering Co., Ltd. to integrate its AI Nose and Smell Language Model technologies into Kenmec's smart factory ecosystem across Asia.

Ainos Inc. announces a 412% year-over-year increase in Q1 2025 revenue, fueled by strong performance of its AI Nose products and strategic partnerships.

Ainos Inc. has amended its convertible promissory note with Li-Kuo Lee, extending the maturity date to May 13, 2025.

Ainos, Inc. and Advanced Semiconductor Engineering, Inc. (ASE) are collaborating to integrate Ainos' AI Nose technology into semiconductor manufacturing for enhanced efficiency, safety, and ESG compliance.

Ainos Inc. has amended its convertible note agreement with ASE Test, extending the maturity date to March 12, 2027, and modifying the conversion price to potentially benefit the noteholder.

Ainos, Inc. announces its financial results for fiscal year 2024, highlighting a strategic shift from COVID-19 testing to AI Nose and VELDONA technologies.

Ainos, Inc. and ugo, Inc. are collaborating to integrate AI Nose technology into robots, enabling them to detect smells for use in industrial safety, healthcare, and public security.

Ainos, Inc. has signed a Memorandum of Understanding with Taiwan Tanabe Seiyaku to collaborate on the manufacturing and promotion of its Sjögren's syndrome drug, VELDONA.

Ainos, Inc. has entered into a third addendum to its product development agreement with Taiwan Carbon Nano Technology Corporation (TCNT), securing exclusive rights to patents for a nitrogen-oxygen separation machine for medical applications.

Ainos, Inc. held its annual meeting on September 27, 2024, where stockholders approved the ratification of the company's auditor and the reservation of shares for special stock awards.

Ainos Inc. has entered into a patent license agreement with Taiwan Carbon Nano Technology Corporation (TCNT), acquiring exclusive rights to gas sensor and medical device patents in exchange for 5.5 million shares of common stock.

Ainos, Inc. announced its Q2 2024 financial results, highlighting progress in clinical trials for feline chronic gingivostomatitis (FCGS) and advancements in its AI-powered point-of-care testing technology.

Ainos, Inc. has received a notice from Nasdaq stating that its stock price has fallen below the required minimum of $1.00 per share for continued listing.

Ainos, Inc. has extended its agreement with Taiwan Carbon Nano Technology Corporation (TCNT) for non-exclusive use of patents related to volatile organic compounds (VOC) and point-of-care testing (POCT) technologies for an additional three months.

Ainos, Inc. announces significant progress in clinical trials for its Ainos Flora device and plans for next-generation development using NVIDIA CUDA technology.